Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Invested Capital (2020 - 2026)

Barinthus Biotherapeutics filings provide 7 years of Invested Capital readings, the most recent being $66.4 million for Q1 2026.

  • On a quarterly basis, Invested Capital fell 42.56% to $66.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $66.4 million, a 42.56% decrease, with the full-year FY2025 number at $74.2 million, down 42.98% from a year prior.
  • Invested Capital hit $66.4 million in Q1 2026 for Barinthus Biotherapeutics, down from $74.2 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $254.8 million in Q2 2022 to a low of $66.4 million in Q1 2026.
  • Median Invested Capital over the past 5 years was $172.0 million (2024), compared with a mean of $170.0 million.
  • Biggest five-year swings in Invested Capital: surged 579.14% in 2022 and later plummeted 46.97% in 2025.
  • Barinthus Biotherapeutics' Invested Capital stood at $243.2 million in 2022, then dropped by 23.11% to $187.0 million in 2023, then plummeted by 30.41% to $130.1 million in 2024, then crashed by 42.98% to $74.2 million in 2025, then dropped by 10.52% to $66.4 million in 2026.
  • The last three reported values for Invested Capital were $66.4 million (Q1 2026), $74.2 million (Q4 2025), and $84.6 million (Q3 2025) per Business Quant data.